LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 204

Search options

  1. Article ; Online: In Memoriam: M. Cristina Kenney, MD, PhD (1949-2023).

    Kuppermann, Baruch D / Palczewski, Krzysztof

    Experimental eye research

    2024  , Page(s) 109805

    Language English
    Publishing date 2024-01-31
    Publishing country England
    Document type Journal Article
    ZDB-ID 80122-7
    ISSN 1096-0007 ; 0014-4835
    ISSN (online) 1096-0007
    ISSN 0014-4835
    DOI 10.1016/j.exer.2024.109805
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 163: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Biosimilars for Retinal Diseases: Understanding the Phase 3 Clinical Trial Design.

    Sharma, Ashish / Kuppermann, Baruch D

    Ophthalmology

    2021  Volume 129, Issue 1, Page(s) 65–66

    MeSH term(s) Biosimilar Pharmaceuticals ; Clinical Trials as Topic ; Drug Approval ; Humans ; Retinal Diseases/drug therapy
    Chemical Substances Biosimilar Pharmaceuticals
    Language English
    Publishing date 2021-09-15
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 392083-5
    ISSN 1549-4713 ; 0161-6420
    ISSN (online) 1549-4713
    ISSN 0161-6420
    DOI 10.1016/j.ophtha.2021.09.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ul II Zs.83: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 533: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.

    Sharma, Ashish / Kumar, Nilesh / Parachuri, Nikulaa / Bandello, Francesco / Loewenstein, Anat / Kuppermann, Baruch D

    Eye (London, England)

    2024  

    Language English
    Publishing date 2024-03-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 91001-6
    ISSN 1476-5454 ; 0950-222X
    ISSN (online) 1476-5454
    ISSN 0950-222X
    DOI 10.1038/s41433-024-03001-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3010: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 603: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Global experience of faricimab in clinical settings - a review.

    Sharma, Ashish / Kumar, Nilesh / Parachuri, Nikulaa / Loewenstein, Anat / Bandello, Francesco / Kuppermann, Baruch D

    Expert opinion on biological therapy

    2024  Volume 24, Issue 4, Page(s) 263–268

    Abstract: Introduction: Faricimab is a bispecific antibody that acts to reduce neoangiogenesis in exudative retinal vascular disorders. It is approved for use in neovascular age-related macular degeneration and diabetic macular edema. We review the published ... ...

    Abstract Introduction: Faricimab is a bispecific antibody that acts to reduce neoangiogenesis in exudative retinal vascular disorders. It is approved for use in neovascular age-related macular degeneration and diabetic macular edema. We review the published efficacy and safety of faricimab in clinical settings.
    Areas covered: A comprehensive literature review was conducted. Based on the 14 published real-world studies, 1127 patients (1204 eyes) were treated with faricimab. The majority of studies (14) included pre-treated patients. Most studies (13) showed central macular thickness improvement. However visual acuity improved in only half of the studies analyzed. Four studies demonstrated an extension of the treatment. Only 4 eyes (0.33%) reported intraocular inflammation and 3 eyes (0.24%) reported retinal pigment epithelial tear.
    Expert opinion: The clinical experience with faricimab to date has the potential to provide a stable visual outcome with reduced treatment burden in cases that are resistant to other approved anti-VEGF agents. There are no major safety concerns based on this data analysis.
    MeSH term(s) Humans ; Antibodies, Bispecific/therapeutic use ; Antibodies, Bispecific/adverse effects ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/therapeutic use ; Macular Degeneration/drug therapy ; Treatment Outcome
    Chemical Substances Antibodies, Bispecific ; Angiogenesis Inhibitors
    Language English
    Publishing date 2024-03-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2024.2336087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy.

    Sharma, Ashish / Kumar, Nilesh / Kuppermann, Baruch D

    JAMA ophthalmology

    2022  Volume 141, Issue 2, Page(s) 128–129

    MeSH term(s) Humans ; Ranibizumab/therapeutic use ; Biosimilar Pharmaceuticals/adverse effects ; Infliximab
    Chemical Substances Ranibizumab (ZL1R02VT79) ; Biosimilar Pharmaceuticals ; Infliximab (B72HH48FLU)
    Language English
    Publishing date 2022-12-15
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2701705-9
    ISSN 2168-6173 ; 2168-6165
    ISSN (online) 2168-6173
    ISSN 2168-6165
    DOI 10.1001/jamaophthalmol.2022.5543
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ul I Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists.

    Sharma, Ashish / Khanani, Arshad M / Parachuri, Nikulaa / Kumar, Nilesh / Bandello, Francesco / Kuppermann, Baruch D

    International journal of retina and vitreous

    2023  Volume 9, Issue 1, Page(s) 6

    Language English
    Publishing date 2023-01-30
    Publishing country England
    Document type Editorial
    ZDB-ID 2836254-8
    ISSN 2056-9920
    ISSN 2056-9920
    DOI 10.1186/s40942-023-00446-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases.

    Sharma, Ashish / Loewenstein, Anat / Parachuri, Nikulaa / Kumar, Nilesh / Kuppermann, Baruch D

    Journal of vitreoretinal diseases

    2023  Volume 7, Issue 6, Page(s) 474–476

    Language English
    Publishing date 2023-09-29
    Publishing country United States
    Document type Journal Article
    ISSN 2474-1272
    ISSN (online) 2474-1272
    DOI 10.1177/24741264231202080
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.

    Sharma, Ashish / Kumar, Nilesh / Parachuri, Nikulaa / Loewenstein, Anat / Bandello, Francesco / Kuppermann, Baruch D

    Expert opinion on biological therapy

    2023  Volume 23, Issue 8, Page(s) 689–692

    Abstract: Introduction: South Asian countries such as India, South Korea, and Japan have played a key role in spearheading the research and development of biosimilars of the anti-vascular endothelial growth factor (anti-VEGF) ranibizumab for retinal diseases. It ... ...

    Abstract Introduction: South Asian countries such as India, South Korea, and Japan have played a key role in spearheading the research and development of biosimilars of the anti-vascular endothelial growth factor (anti-VEGF) ranibizumab for retinal diseases. It is important to understand how this region is preparing for the next decade in the field of anti-VEGF biosimilars for retinal diseases.
    Areas covered: We discuss the existing anti-VEGF ranibizumab biosimilars along with the biosimilars that might receive approval in the coming decade. Furthermore, we discuss the development status of aflibercept biosimilars that might receive approval as soon as the aflibercept patent expires.
    Expert opinion: The South Asian region seems to be well prepared, with multiple ranibizumab and aflibercept biosimilars in the pipeline. However, it has to be seen whether these therapies will have widespread global clearance or will simply obtain approval from the Asian regional authorities.
    MeSH term(s) Humans ; Ranibizumab ; Angiogenesis Inhibitors/therapeutic use ; Biosimilar Pharmaceuticals/therapeutic use ; Bevacizumab ; Vascular Endothelial Growth Factor A ; Asia, Southern ; Retinal Diseases/drug therapy ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Vascular Endothelial Growth Factors ; Recombinant Fusion Proteins/therapeutic use ; Intravitreal Injections
    Chemical Substances Ranibizumab (ZL1R02VT79) ; Angiogenesis Inhibitors ; Biosimilar Pharmaceuticals ; Bevacizumab (2S9ZZM9Q9V) ; Vascular Endothelial Growth Factor A ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Vascular Endothelial Growth Factors ; Recombinant Fusion Proteins
    Language English
    Publishing date 2023-07-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2023.2239706
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Aflibercept biosimilars - update on the development progress.

    Sharma, Ashish / Loewenstein, Anat / Kumar, Nilesh / Parachuri, Nikulaa / Bandello, Francesco / Kuppermann, Baruch D

    Eye (London, England)

    2023  Volume 38, Issue 5, Page(s) 824–825

    MeSH term(s) Humans ; Biosimilar Pharmaceuticals ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins
    Chemical Substances Biosimilar Pharmaceuticals ; aflibercept (15C2VL427D) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Recombinant Fusion Proteins
    Language English
    Publishing date 2023-11-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 91001-6
    ISSN 1476-5454 ; 0950-222X
    ISSN (online) 1476-5454
    ISSN 0950-222X
    DOI 10.1038/s41433-023-02813-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3010: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 603: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?

    Sharma, Ashish / Kumar, Nilesh / Parachuri, Nikulaa / Regillo, Carl / Bandello, Francesco / Kuppermann, Baruch D

    Eye (London, England)

    2022  Volume 37, Issue 10, Page(s) 1953–1954

    MeSH term(s) Humans ; Ranibizumab/therapeutic use ; Biosimilar Pharmaceuticals ; Retina ; Physicians ; Angiogenesis Inhibitors/therapeutic use
    Chemical Substances Ranibizumab (ZL1R02VT79) ; Biosimilar Pharmaceuticals ; Angiogenesis Inhibitors
    Language English
    Publishing date 2022-10-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 91001-6
    ISSN 1476-5454 ; 0950-222X
    ISSN (online) 1476-5454
    ISSN 0950-222X
    DOI 10.1038/s41433-022-02287-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3010: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 603: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top